Cantor Fitzgerald Reiterates Overweight Rating on PTC Therapeutics, Inc. (PTCT)

Market Context

PTC Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $78.52 with a market capitalization of $6.1B. The stock has gained 64.7% over the past 52 weeks.

Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for PTC Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for PTC Therapeutics, Inc.

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 16, 2026	Cantor Fitzgerald	Overweight	N/A
Jul 07, 2026	RBC Capital	Sector Perform	N/A
May 27, 2026	Jefferies	Buy	N/A
May 08, 2026	TD Cowen	Buy	N/A
May 08, 2026	RBC Capital	Sector Perform	N/A

Related Tools: Analyst Ratings Dashboard | View PTCT Stock Page